Molecular profile of patients with myelofibrosis: a 10-year experience.

Autor: Dias LFS; Hospital Israelita Albert Einstein, São Paulo, SP, Brazil., Pereira CLM; Hospital Israelita Albert Einstein, São Paulo, SP, Brazil., Centurião NF; Hospital Israelita Albert Einstein, São Paulo, SP, Brazil., Nascimento JZMD; Hospital Israelita Albert Einstein, São Paulo, SP, Brazil., Ribeiro AAF; Hospital Israelita Albert Einstein, São Paulo, SP, Brazil., Hamerschlak N; Hospital Israelita Albert Einstein, São Paulo, SP, Brazil., Marques CP; Hospital Israelita Albert Einstein, São Paulo, SP, Brazil., Lima ACV; Hospital Israelita Albert Einstein, São Paulo, SP, Brazil., Costa LND; Hospital Israelita Albert Einstein, São Paulo, SP, Brazil., Silva AFD; Hospital Israelita Albert Einstein, São Paulo, SP, Brazil., Lima VJT; Hospital Israelita Albert Einstein, São Paulo, SP, Brazil., Kerbauy MN; Hospital Israelita Albert Einstein, São Paulo, SP, Brazil., Kerbauy LN; Hospital Israelita Albert Einstein, São Paulo, SP, Brazil., Arcuri LJ; Hospital Israelita Albert Einstein, São Paulo, SP, Brazil., Campregher PV; Hospital Israelita Albert Einstein, São Paulo, SP, Brazil., Rocha JDAD; Hospital Israelita Albert Einstein, São Paulo, SP, Brazil., Datoguia TS; Hospital Israelita Albert Einstein, São Paulo, SP, Brazil., Santos FPS; Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.
Jazyk: angličtina
Zdroj: Einstein (Sao Paulo, Brazil) [Einstein (Sao Paulo)] 2023 Jan 06; Vol. 21, pp. eAO0100. Date of Electronic Publication: 2023 Jan 06 (Print Publication: 2023).
DOI: 10.31744/einstein_journal/2023AO0100
Abstrakt: Objective: To analyze the karyotype test and myeloid panel with next-generation sequencing findings in patients with myelofibrosis, and to compare transplant characteristics in patients referred for bone marrow transplantation.
Methods: Retrospective, single-center study with patients diagnosed with myelofibrosis treated at Hospital Israelita Albert Einstein between 2010 and 2020.
Results: A total of 104 patients with myelofibrosis were examined. Patients who had not been submitted to tests in our service were excluded. The final sample comprised 69 patients. Of these 69, 56 were submitted to karyotyping and 22 to myeloid panel with next-generation sequencing. Karyotype was normal in 60% of the patients and altered in 40%. The prevalence of high-risk molecular mutations was higher in patients referred for bone marrow transplantation (100% versus 50%). The median follow-up of transplant patients was 2.4 years and the overall survival at 2 years was 80% (95%CI: 62-100%).
Conclusion: The molecular analysis enables estimating the patient's risk and thus instituting more aggressive treatment such as bone marrow transplant for patients at higher risk, being a relevant tool to guide therapy. Given the significance of molecular analysis for therapeutic decision-making in myelofibrosis, collection and disclosure of data on the prevalence of cytogenetic changes and findings of next-generation sequencing in affected patients is important.
Databáze: MEDLINE
Externí odkaz: